Argos Therapeutics Inc (NASDAQ:ARGS) offered an update on the ADAPT study, which is a Phase III multi-center trial of Rocapuldencel-T plus sunitinib targeting mRCC, subsequent to talks with the FDA.
Argos posted that Arcelis® comes in the list of precision immunotherapy know-hows. This specific technology captures variant and mutated antigens explicit to subject’s individual disease. It is developed to overcome immunosuppression by discharging a specifically directed, long-lasting memory ‘T’ cell response in nonexistence of adjuvants that may be connected with toxicity.
The know-how is possibly pertinent to the cure of different kinds of cancers and infectious ailments, and is intended to resolve many of the commercialization and manufacturing tasks that have clogged other personalized immunotherapies.
The Arcelis® technique uses just biopsy or a small ailment sample as the basis of disease-related antigens, and the subject’s dendritic cells, which are amplified from cells grouped by a single leukapheresis course. The proprietary procedure exploits RNA separated from the subject’s ailment sample to prepare dendritic cells for targeting ailment-specific antigens.
These stimulated, antigen-full dendritic cells are framed with the subject’s own plasma, and administered via intradermal injection as a tailored immunotherapy. Argos is an immuno-oncology unit focused on the devising and commercialization of customized immunotherapies for the treatment of infectious ailments and cancer utilizing Arcelis® technology.
Argos’ offering, Rocapuldencel-T, is being evaluated in the planned ADAPT Phase III study for metastatic renal cell carcinoma. Moreover, it is being assessed in a Phase 2 trial as neoadjuvant therapy for renal cell carcinoma. Argos is advancing a unique Arcelis®-based offering known as AGS-004, for human immunodeficiency virus. It is currently being evaluated in an investigator-introduced Phase II study intended at HIV removal in adult subjects.
In the previous trading session, the shares of Argos declined more than 4% to close the day at $0.405.